Evaluation and option agreement with GSK Consumer Healthcare
Filed with ASX · · 3 pages · English
• Key terms of any definitive sales and marketing agreement to be contingent on factors including results of Cann’s Phase 3 clinical trial and path to regulatory approval as well as GSK Consumer Healthcare’s marketing evaluation 6 April 2022 - Cann Group Limited (ASX: CAN) (Cann or the Company) announced today that it has entered into an exclusive evaluation and option agreement with GSK Consumer
Earlier from Cann
- Satipharm CBD products get green light from UK FSA
- Mildura facility practical completion & ODC permit granted
- Cann to begin recruitment for CBD phase 3 clinical trial
- Cann granted GMP licence & other regulatory updates
- Results of Share Purchase Plan offer
Later from Cann
- ODC manufacture permit granted for Mildura
- New funding arrangements with National Australia Bank
- Monthly Activities/Appendix 4C Cash Flow Report
- GMP manufacturing licence granted for Mildura
- Cann releases FY22 results
Follow Cann into a list and get an email when it puts out news.
Follow Cann